JP2001072572A - Skin preparation for external use - Google Patents
Skin preparation for external useInfo
- Publication number
- JP2001072572A JP2001072572A JP25443199A JP25443199A JP2001072572A JP 2001072572 A JP2001072572 A JP 2001072572A JP 25443199 A JP25443199 A JP 25443199A JP 25443199 A JP25443199 A JP 25443199A JP 2001072572 A JP2001072572 A JP 2001072572A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- acid
- extracts
- extract
- elastin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 102000016942 Elastin Human genes 0.000 claims abstract description 48
- 108010014258 Elastin Proteins 0.000 claims abstract description 48
- 229920002549 elastin Polymers 0.000 claims abstract description 48
- 239000000284 extract Substances 0.000 claims abstract description 25
- 241000251468 Actinopterygii Species 0.000 claims abstract description 19
- 230000003213 activating effect Effects 0.000 claims abstract description 15
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 8
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 claims abstract description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims abstract description 6
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims abstract description 5
- 239000013543 active substance Substances 0.000 claims abstract description 5
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 4
- 229960000458 allantoin Drugs 0.000 claims abstract description 4
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 4
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 4
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 4
- 229940109850 royal jelly Drugs 0.000 claims abstract description 4
- 239000000126 substance Substances 0.000 claims abstract description 4
- OQSYGPGBSYLQDV-UHFFFAOYSA-N 2-(propan-2-ylamino)hexanoic acid Chemical compound CCCCC(C(O)=O)NC(C)C OQSYGPGBSYLQDV-UHFFFAOYSA-N 0.000 claims abstract description 3
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 3
- 241001131796 Botaurus stellaris Species 0.000 claims abstract description 3
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 claims abstract description 3
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims abstract description 3
- 102000016943 Muramidase Human genes 0.000 claims abstract description 3
- 108010014251 Muramidase Proteins 0.000 claims abstract description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims abstract description 3
- 229960003720 enoxolone Drugs 0.000 claims abstract description 3
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000001685 glycyrrhizic acid Substances 0.000 claims abstract description 3
- 229960004949 glycyrrhizic acid Drugs 0.000 claims abstract description 3
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims abstract description 3
- 235000019410 glycyrrhizin Nutrition 0.000 claims abstract description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 3
- 239000004325 lysozyme Substances 0.000 claims abstract description 3
- 235000010335 lysozyme Nutrition 0.000 claims abstract description 3
- 229960000274 lysozyme Drugs 0.000 claims abstract description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims abstract description 3
- 210000002826 placenta Anatomy 0.000 claims abstract description 3
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 3
- 229960004889 salicylic acid Drugs 0.000 claims abstract description 3
- 210000000952 spleen Anatomy 0.000 claims abstract description 3
- 239000012138 yeast extract Substances 0.000 claims abstract description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 239000004310 lactic acid Substances 0.000 claims description 5
- 235000014655 lactic acid Nutrition 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 241000561734 Celosia cristata Species 0.000 claims description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 210000001520 comb Anatomy 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 claims description 3
- 235000019154 vitamin C Nutrition 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- 229940041514 candida albicans extract Drugs 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 241000222336 Ganoderma Species 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- -1 7-oryzanol Chemical compound 0.000 abstract description 8
- 239000004615 ingredient Substances 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 6
- 239000002440 industrial waste Substances 0.000 abstract description 4
- 240000008397 Ganoderma lucidum Species 0.000 abstract description 2
- 235000001637 Ganoderma lucidum Nutrition 0.000 abstract description 2
- 239000002253 acid Substances 0.000 abstract description 2
- 241000186660 Lactobacillus Species 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 229940039696 lactobacillus Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 description 29
- 239000000243 solution Substances 0.000 description 28
- 239000000203 mixture Substances 0.000 description 20
- 239000012071 phase Substances 0.000 description 19
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 235000019688 fish Nutrition 0.000 description 16
- 239000008213 purified water Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 239000008346 aqueous phase Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 239000002537 cosmetic Substances 0.000 description 9
- 239000006071 cream Substances 0.000 description 9
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 8
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 239000006210 lotion Substances 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- 206010040954 Skin wrinkling Diseases 0.000 description 6
- 229960000541 cetyl alcohol Drugs 0.000 description 6
- 239000003205 fragrance Substances 0.000 description 6
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 230000037303 wrinkles Effects 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 230000003020 moisturizing effect Effects 0.000 description 5
- 230000037394 skin elasticity Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- 102000016387 Pancreatic elastase Human genes 0.000 description 4
- 108010067372 Pancreatic elastase Proteins 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229940075507 glyceryl monostearate Drugs 0.000 description 4
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 4
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 4
- 230000009759 skin aging Effects 0.000 description 4
- 229940032094 squalane Drugs 0.000 description 4
- 229940058015 1,3-butylene glycol Drugs 0.000 description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 235000013871 bee wax Nutrition 0.000 description 3
- 239000012166 beeswax Substances 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003974 emollient agent Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 229960002216 methylparaben Drugs 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000002884 skin cream Substances 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 229940099259 vaseline Drugs 0.000 description 3
- 230000002087 whitening effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 2
- ASKIVFGGGGIGKH-UHFFFAOYSA-N 2,3-dihydroxypropyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(O)CO ASKIVFGGGGIGKH-UHFFFAOYSA-N 0.000 description 2
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 229940035044 sorbitan monolaurate Drugs 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- 239000003871 white petrolatum Substances 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- TVPZDSSZKMMCLB-UHFFFAOYSA-N 3,8,10-trihydroxy-9,11-bis(3-methylbut-2-enyl)-6-(2-methylprop-1-enyl)-6h-chromeno[4,3-b]chromen-7-one Chemical compound C12=CC=C(O)C=C2OC(C=C(C)C)C2=C1OC1=C(CC=C(C)C)C(O)=C(CC=C(C)C)C(O)=C1C2=O TVPZDSSZKMMCLB-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- TVPZDSSZKMMCLB-QHCPKHFHSA-N Artelastin Natural products O=C1c2c(O)c(C/C=C(\C)/C)c(O)c(C/C=C(\C)/C)c2OC=2c3c(O[C@@H](/C=C(\C)/C)C1=2)cc(O)cc3 TVPZDSSZKMMCLB-QHCPKHFHSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 102100033041 Carbonic anhydrase 13 Human genes 0.000 description 1
- 241000252203 Clupea harengus Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000276438 Gadus morhua Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 101000867860 Homo sapiens Carbonic anhydrase 13 Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- MJNIWUJSIGSWKK-BBANNHEPSA-N Riboflavin butyrate Chemical compound CCCC(=O)OC[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-BBANNHEPSA-N 0.000 description 1
- 241001125046 Sardina pilchardus Species 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical class C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 235000019516 cod Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229940074052 glyceryl isostearate Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 235000019514 herring Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 150000002814 niacins Chemical class 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 231100000121 skin sensitizing Toxicity 0.000 description 1
- 229950002760 sodium gualenate Drugs 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- GEYJUFBPCGDENK-UHFFFAOYSA-M sodium;3,8-dimethyl-5-propan-2-ylazulene-1-sulfonate Chemical compound [Na+].CC(C)C1=CC=C(C)C2=C(S([O-])(=O)=O)C=C(C)C2=C1 GEYJUFBPCGDENK-UHFFFAOYSA-M 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】この発明は、保湿作用及び真
皮線維芽細胞活性化作用が相乗的に増強され、しわの発
生、皮膚弾性の低下といった皮膚老化症状の防止あるい
は改善に有効な、皮膚外用剤に関する。詳細には、魚皮
由来の加水分解エラスチン溶液と、細胞賦活成分,抗炎
症成分から選択される1種又は2種以上を配合した、皮
膚外用剤に関する。TECHNICAL FIELD The present invention relates to an external use for skin which has a synergistic enhancement of moisturizing action and dermal fibroblast activating action and is effective for preventing or improving skin aging symptoms such as wrinkles and reduced skin elasticity. Agent. More specifically, the present invention relates to a skin external preparation comprising a fish skin-derived hydrolyzed elastin solution and one or more selected from a cell activating component and an anti-inflammatory component.
【0002】[0002]
【従来の技術】エラスチンは、弾性繊維の主成分であ
り、不溶性の蛋白質で、靭帯,皮膚等の伸縮性に富む臓
器に存在する。このエラスチンは皮膚の保護並びに保湿
剤として化粧料への配合が期待されてきた。しかしなが
ら、エラスチンは不溶性であるため、そのままでは化粧
料処方中に配合することが困難であった。そこで、エラ
スチンを可溶化して配合する試みがなされている。例え
ば、可溶性の加水分解エラスチンを配合した化粧料(特
開昭53−72832)、水溶性天然エラスチン及び/
又は酵素により可溶化処理したエラスチン加水分解物を
配合した毛髪及び皮膚化粧料(特開昭54−10523
8)、エラスターゼにより可溶化した化粧料用エラスチ
ン(特開昭58−192812)、可溶性エラスチン及
び/又は可溶化エラスチンと保湿剤及び/又は生理活性
物質を併用した皮膚化粧料(特開昭59−13930
8)、エラスチン加水分解物を乳化剤として配合した皮
膚用水中油型エマルション(特開昭59−23100
7)、分子量15,000〜300,000のウシ項靭
帯由来エラスチンを配合した皮膚及び毛髪用組成物(特
開昭60−258107)、分子量200,000以上
のエラスチン加水分解物を乳化剤として配合した乳化組
成物(特開昭63−302934)、1,3-ブチレングリ
コール,プロピレングリコールによりエラスチン加水分
解物水溶液を安定化する方法(特開平2−16721
1)等の技術が開示されている。しかしながらこれらの
エラスチン加水分解物は、牛や豚,鶏など家畜動物を基
原にするものが殆どであった。2. Description of the Related Art Elastin is a main component of elastic fibers, is an insoluble protein, and is present in highly elastic organs such as ligaments and skin. This elastin has been expected to be incorporated into cosmetics as a skin protection and moisturizing agent. However, since elastin is insoluble, it has been difficult to incorporate it in a cosmetic formulation as it is. Therefore, attempts have been made to solubilize and mix elastin. For example, cosmetics containing soluble hydrolyzed elastin (JP-A-53-72832), water-soluble natural elastin and / or
Or a hair and skin cosmetic containing an elastin hydrolyzate solubilized by an enzyme (JP-A-54-10523)
8), elastin for cosmetics solubilized by elastase (JP-A-58-192812), skin cosmetics using soluble elastin and / or solubilized elastin in combination with a humectant and / or a physiologically active substance (JP-A-59-1982). 13930
8), an oil-in-water emulsion for skin containing an elastin hydrolyzate as an emulsifier (JP-A-59-23100)
7), a composition for skin and hair containing elastin derived from bovine ligament having a molecular weight of 15,000 to 300,000 (JP-A-60-258107), and an elastin hydrolyzate having a molecular weight of 200,000 or more was compounded as an emulsifier. A method of stabilizing an elastin hydrolyzate aqueous solution with an emulsified composition (JP-A-63-302934), 1,3-butylene glycol and propylene glycol (JP-A-2-16721)
Techniques such as 1) are disclosed. However, most of these elastin hydrolysates are based on domestic animals such as cattle, pigs, and chickens.
【0003】また、魚皮にエラスチンが豊富に含まれて
いることは既に公知である。しかしながら、水産加工業
から生じる魚皮は産業廃棄物とされており、年間を通じ
て多量に廃棄されている。近年の産業廃棄物の有効利用
に関する研究により、魚皮からエラスチンを加水分解し
てコラーゲンとともに単離する技術も開示されている
(特開平5−202097)。It is already known that fish skin is rich in elastin. However, fish skin generated from the fishery processing industry is regarded as industrial waste and is disposed of in large quantities throughout the year. Recent research on the effective use of industrial wastes has disclosed a technique for hydrolyzing elastin from fish skin and isolating it together with collagen (Japanese Patent Laid-Open No. 5-202097).
【0004】[0004]
【発明が解決しようとする課題】本発明においては、産
業廃棄物であった魚皮を有効利用し、また、エラスチン
の有する保湿及び皮膚保護の効果を十分に発揮し、皮膚
の老化防止に有用な皮膚外用剤を提供することを目的と
した。In the present invention, fish skin, which is an industrial waste, is effectively used, and the effect of elastin on the moisturizing and skin protection is sufficiently exhibited, which is useful for preventing skin aging. It is an object of the present invention to provide a skin external preparation.
【0005】[0005]
【課題を解決するための手段】本発明者は、前記問題点
に鑑み研究を行った結果、魚皮由来の加水分解エラスチ
ン溶液と細胞賦活成分及び抗炎症成分より選択される1
種又は2種以上の成分を皮膚外用剤に配合することによ
り、エラスチンの有する保湿及び皮膚保護効果を少量の
配合で十分に発揮し、さらに皮膚老化防止作用にも優れ
ることを見いだし、本発明を完成するに至った。Means for Solving the Problems The present inventor conducted a study in view of the above problems, and as a result, selected from a fish skin-derived hydrolyzed elastin solution, a cell activating component and an anti-inflammatory component.
By blending the seed or two or more components with the external preparation for skin, the moisturizing and skin-protecting effects of elastin can be sufficiently exerted with a small amount of blending, and furthermore, the present invention has been found to be excellent in preventing skin aging. It was completed.
【0006】[0006]
【発明の実施の形態】本発明の実施の形態を説明する。Embodiments of the present invention will be described.
【0007】本発明で使用する魚皮由来加水分解エラス
チン溶液は、魚皮を酸若しくはアルカリ、またはエラス
ターゼ,ペプシン,トリプシンなどの蛋白分解酵素を用
いて、加水分解して得られる溶液を用いる。その際、魚
皮由来加水分解エラスチン溶液のpHは、皮膚外用剤に
配合するその他の成分及び製剤への影響を考慮して、
3.5〜4.5の範囲に調整することが好ましい。ま
た、魚皮由来加水分解エラスチン溶液を得る魚の種類
は、特に限定されず、例えばタラ,サバ,サケ,ニシ
ン,タイ,マグロ,イワシ等が挙げられる。The hydrolyzed elastin solution derived from fish skin used in the present invention is a solution obtained by hydrolyzing fish skin using an acid or an alkali, or a proteolytic enzyme such as elastase, pepsin, and trypsin. At that time, the pH of the fish skin-derived hydrolyzed elastin solution is determined in consideration of the effect on other components and the formulation to be mixed in the external preparation for skin.
It is preferable to adjust the value in the range of 3.5 to 4.5. The type of fish from which the hydrolyzed elastin solution derived from fish skin is obtained is not particularly limited, and examples thereof include cod, mackerel, salmon, herring, thailand, tuna, and sardine.
【0008】本発明本で使用する魚皮由来加水分解エラ
スチン溶液は例えば、タラの皮を粉砕し精製水と混合し
て,95℃にて1時間加熱した後、エラスターゼを添加
して40℃で30時間部分加水分解を行い、次いで95
℃で1時間加熱して酵素反応を停止し、pHを4.0に
調整し、メンブランフィルターにて除菌濾過を行うこと
により、調製することができる。[0008] The hydrolyzed elastin solution derived from fish skin used in the present invention is, for example, crushed cod skin, mixed with purified water, heated at 95 ° C for 1 hour, and added elastase at 40 ° C. Perform partial hydrolysis for 30 hours, then 95
It can be prepared by heating at 1 ° C. for 1 hour to stop the enzymatic reaction, adjusting the pH to 4.0, and performing sterile filtration with a membrane filter.
【0009】本発明で使用する魚皮由来加水分解エラス
チン溶液の皮膚外用剤への配合量は、その効果や製剤の
安定性の点から考え、0.0001〜5.0重量%の濃
度範囲とすることが好ましい。[0009] The amount of the hydrolyzed elastin solution derived from fish skin used in the present invention in the external preparation for skin is considered to be 0.0001 to 5.0% by weight in consideration of its effect and stability of the preparation. Is preferred.
【0010】本発明の皮膚外用剤では、細胞賦活成分及
び抗炎症成分から選択される1種又は2種以上を配合す
る。In the skin external preparation of the present invention, one or more selected from a cell activating component and an anti-inflammatory component are blended.
【0011】細胞賦活成分としては、通常の皮膚外用剤
に用いられるものであれば、種類や基原は問わない。例
えば、細胞賦活成分が、炭素数2〜22の2-ヒドロキシ
カルボン酸及びその塩並びに誘導体、ビタミンC,E,
P関連化合物を除くビタミン様作用物質、核酸関連物
質、血清除蛋白抽出物、脾臓抽出物、胎盤抽出物、鶏冠
抽出物、ロイヤルゼリー、霊芝抽出物、酵母抽出物、乳
酸菌抽出物、ビフィズス菌抽出物、ニガリ成分等が例示
される。The cell activating component may be of any type and origin, as long as it is used in ordinary skin external preparations. For example, the cell activating component is 2-hydroxycarboxylic acid having 2 to 22 carbon atoms and salts and derivatives thereof, vitamin C, E,
Vitamin-like active substance except P-related compound, nucleic acid-related substance, serum deproteinized extract, spleen extract, placenta extract, cockscomb extract, royal jelly, reishi extract, yeast extract, lactic acid extract, bifidobacterium An extract, a bittern component, etc. are illustrated.
【0012】本発明に使用される細胞賦活効果を有する
炭素数2〜22のα−ヒドロキシカルボン酸及びその塩
並びにその誘導体としては、特に限定されないが、中で
も真皮線維芽細胞賦活効果から炭素数2〜6の短鎖α−
ヒドロキシカルボン酸たとえば、α−ヒドロキシ酢酸,
乳酸,リンゴ酸,酒石酸,ピルビン酸,クエン酸及びそ
の塩、またα−ヒドロキシ酸の経皮吸収を改善した、α
−ヒドロキシ酸のアルキルエステル,コレステロールエ
ステル,配糖体,ホスファチジルエステル等が好ましく
用いられる。The α-hydroxycarboxylic acid having 2 to 22 carbon atoms and its salts and derivatives thereof having a cell activating effect used in the present invention is not particularly limited. ~ 6 short chain α-
Hydroxycarboxylic acids such as α-hydroxyacetic acid,
Improved dermal absorption of lactic acid, malic acid, tartaric acid, pyruvic acid, citric acid and salts thereof, and α-hydroxy acid.
-Alkyl esters of hydroxy acids, cholesterol esters, glycosides, phosphatidyl esters and the like are preferably used.
【0013】さらに、ビタミンC,E,P関連化合物を
除くビタミン様作用物質としては、ビタミンA油,酢酸
レチノール等のビタミンA類、リボフラビン,酪酸リボ
フラビン等のビタミンB2類、塩酸ピリドキシン等のビ
タミンB6類、L−ニコチン酸,ニコチン酸アミド,ニ
コチン酸ベンジル等のニコチン酸類、及びビオチン等の
ビタミンH類等が例示される。Further, as vitamin-like active substances excluding vitamin C, E and P-related compounds, vitamin A such as vitamin A oil and retinol acetate; vitamin B2 such as riboflavin and riboflavin butyrate; and vitamin B6 such as pyridoxine hydrochloride. And nicotinic acids such as L-nicotinic acid, nicotinamide and benzyl nicotinate, and vitamin Hs such as biotin.
【0014】本発明で用いられる核酸関連物質としては
特に限定されないが、デオキシリボ核酸及びその塩,ア
デノシン三リン酸,アデノシン二リン酸などのアデニル
酸誘導体及びそれらの塩,リボ核酸及びその塩,グアニ
ン,キサンチン及びそれらの誘導体並びにそれらの塩な
どが例示される。The nucleic acid-related substance used in the present invention is not particularly limited, but includes deoxyribonucleic acid and salts thereof, adenylic acid derivatives such as adenosine triphosphate and adenosine diphosphate and salts thereof, ribonucleic acid and salts thereof, and guanine. , Xanthine and their derivatives and their salts.
【0015】抗炎症成分としては、通常の皮膚外用剤に
用いられるものであれば、種類や基原は問わない。例え
ば、グリチルチリン酸,グリチルレチン酸,イソプロピ
ルアミノカプロン酸,アズレン,リゾチーム,サリチル
酸,γ−オリザノール,アラントイン及びそれらの誘導
体並びにそれらの塩等が例示される。The type and base of the anti-inflammatory component are not limited as long as it is used in ordinary skin external preparations. Examples thereof include glycyrrhizic acid, glycyrrhetinic acid, isopropylaminocaproic acid, azulene, lysozyme, salicylic acid, γ-oryzanol, allantoin, derivatives thereof, and salts thereof.
【0016】上記の細胞賦活成分及び抗炎症成分の皮膚
外用剤への配合量としては、製剤安定性への影響やバイ
オアベイラビリティ等を考慮すると、0.0001〜5
重量%程度が適当である。The amount of the above-mentioned cell activating component and anti-inflammatory component to be added to the external preparation for skin may be 0.0001 to 5 in consideration of the effect on the stability of the preparation and the bioavailability.
A suitable amount is about weight%.
【0017】本発明においては、魚皮由来加水分解エラ
スチン溶液と細胞賦活成分及び抗炎症成分から選択され
る1種又は2種以上を含有させた皮膚外用剤を提供し得
るが、皮膚外用剤としては、ローション,乳剤,クリー
ム,軟膏等の形態をとることができる。またさらに、柔
軟性化粧水,収れん性化粧水,洗浄用化粧水などの化粧
水類、エモリエントクリーム,モイスチュアクリーム,
マッサージクリーム,クレンジングクリーム,メイクア
ップクリーム等のクリーム類、エモリエント乳液,モイ
スチュア乳液,ナリシング乳液,クレンジング乳液など
の乳液類、ゼリー状パック,ピールオフパック,洗い流
しパック,粉末パックなどのパック類、美容液、及び洗
顔料といった種々の製剤形態の化粧料としても提供する
ことができる。In the present invention, a skin external preparation containing a hydrolyzed elastin solution derived from fish skin and one or more selected from a cell activating component and an anti-inflammatory component can be provided. Can take the form of lotions, emulsions, creams, ointments and the like. Furthermore, lotions such as flexible lotion, astringent lotion, lotion for washing, emollient cream, moisture cream,
Creams such as massage creams, cleansing creams, and makeup creams, emulsions such as emollient emulsions, moisture emulsions, nourishing emulsions, and cleansing emulsions, packs such as jelly packs, peel-off packs, rinse-off packs, powder packs, and serums. And cosmetic preparations of various preparation forms such as face wash.
【0018】本発明においてはさらに、美白成分や,保
湿剤,抗酸化剤,紫外線吸収剤等、他の有効成分を併用
することもでき、日焼け止め化粧料,老化防止用化粧
料、美白剤などの薬用化粧料あるいは医薬部外品などと
して提供することもできる。In the present invention, other active ingredients such as a whitening ingredient, a humectant, an antioxidant, an ultraviolet absorber and the like can be used in combination, and a sunscreen cosmetic, an antiaging cosmetic, a whitening agent, etc. Can be provided as cosmeceuticals or quasi-drugs.
【0019】[0019]
【実施例】まず本発明の実施例に使用した魚皮由来加水
分解エラスチン溶液の製造例を示す。EXAMPLES First, a production example of a hydrolyzed elastin solution derived from fish skin used in Examples of the present invention will be described.
【0020】[製造例1]タラ皮由来エラスチン溶液 凍結したタラの皮を粉砕し、3重量倍の精製水と混合す
る。この混合物を95℃に加熱した後、静置し放冷す
る。エラスターゼを添加して、40℃で30時間反応さ
せ、部分的に加水分解する。次いで95℃で1時間加熱
して、酵素反応を停止させ、濾過して、未加水分解物及
び残査脂肪を除去する。さらに、メンブランフィルター
を用いて除菌濾過を行い、タラ皮由来エラスチン溶液を
得た。このタラ皮由来エラスチン溶液のpHは、4.0
であった。[Manufacturing Example 1] Cod skin-derived elastin solution Frozen cod skin is ground and mixed with 3 times by weight of purified water. After heating this mixture to 95 ° C., it is allowed to stand and cool. Elastase is added and reacted at 40 ° C. for 30 hours to partially hydrolyze. The enzyme reaction is then stopped by heating at 95 ° C. for 1 hour and filtered to remove unhydrolysates and residual fat. Furthermore, sterilization filtration was performed using a membrane filter, and an elastin solution derived from cod skin was obtained. The pH of this elastin solution derived from cod skin is 4.0.
Met.
【0021】製造例1に示したタラ皮由来エラスチン溶
液を用いた実施例により、本発明の特徴について詳細に
説明する。The characteristics of the present invention will be described in detail with reference to Examples using the cod skin-derived elastin solution shown in Production Example 1.
【0022】細胞賦活成分,抗炎症成分と、製造例1に
示したタラ皮由来エラスチン溶液を表1に示すように用
いて、下記の処方により、皮膚用クリームを調製した。A skin cream was prepared by using the cell activating component, the anti-inflammatory component, and the cod skin-derived elastin solution shown in Production Example 1 as shown in Table 1, according to the following formulation.
【0023】 [実施例1〜実施例4,比較例1〜比較例6]皮膚用クリーム (1)ミツロウ 6.0(重量%) (2)セタノール 5.0 (3)還元ラノリン 8.0 (4)スクワラン 37.5 (5)脂肪酸グリセリン 4.0 (6)親油型モノステアリン酸グリセリン 2.0 (7)ポリオキシエチレン(20EO) ソルビタンモノラウレート 2.0 (8)プロピレングリコール 5.0 (9)パラヒドロキシ安息香酸メチル 0.1 (10)精製水 全量を100とする量 (11)表1に示した成分 表1記載の通り (12)香料 0.2 製法:(1)〜(7)の油相成分を混合,溶解して均一と
し、75℃に加熱する。一方、(8)〜(10)の水相成分を
混合,溶解して75℃に加熱する。次いで、上記水相成
分に油相成分を添加して予備乳化した後、ホモミキサー
にて均一に乳化する。その後冷却し、50℃にて(11),
(12)を添加,混合する。[Examples 1 to 4 and Comparative Examples 1 to 6] Skin cream (1) Beeswax 6.0 (% by weight) (2) Cetanol 5.0 (3) Reduced lanolin 8.0 ( 4) Squalane 37.5 (5) Fatty acid glycerin 4.0 (6) Lipophilic glyceryl monostearate 2.0 (7) Polyoxyethylene (20EO) sorbitan monolaurate 2.0 (8) Propylene glycol 0 (9) Methyl parahydroxybenzoate 0.1 (10) Purified water Amount based on the total amount of 100 (11) Components shown in Table 1 As described in Table 1 (12) Fragrance 0.2 Production method: (1)- The oil phase component of (7) is mixed and dissolved to make it uniform, and heated to 75 ° C. On the other hand, the aqueous phase components (8) to (10) are mixed and dissolved and heated to 75 ° C. Next, after the oil phase component is added to the water phase component and pre-emulsified, the mixture is uniformly emulsified by a homomixer. After that, it is cooled and at 50 ° C (11),
Add (12) and mix.
【0024】[0024]
【表1】 [Table 1]
【0025】上記の実施例1〜実施例4及び比較例1〜
6について、3ヶ月間の実使用試験を行った。パネラー
として、皮膚の乾燥症状を気にしている40歳代〜60
歳代の男女、顕著なしわの発生若しくは弾性の低下など
の皮膚症状を有する40歳代〜60歳代の女性、及び顕
著な肌荒れ症状を呈する20歳代〜50歳代の女性を用
い、それぞれ1群20名とした。使用試験は、各群に実
施例及び比較例のそれぞれをブラインドにて使用させ、
使用試験開始前と使用試験終了後の皮膚の状態を観察し
て行った。乾燥症状,しわ及び皮膚弾性の改善状況につ
いては、3ヶ月後の肌が使用前と比べて潤い,しわ及び
皮膚弾性が改善したと回答したパネルの数にて、表2に
示した。また、肌荒れについては、表3に示す判断基準
に従って皮膚の状態を点数化し、20名の平均値により
使用試験開始前と使用試験終了後を比較して表4に示し
た。The above Examples 1 to 4 and Comparative Examples 1 to
6 was subjected to a three-month actual use test. As a panelist, 40s to 60s worried about skin dryness
Using men and women in their twenties, women in their forties to sixties who have skin symptoms such as remarkable wrinkles or reduced elasticity, and women in their twenties to fifties who exhibit remarkable skin roughness, There were 20 people in each group. In the use test, each group was allowed to use each of the examples and comparative examples with blinds,
The state of the skin was observed before the start of the use test and after the end of the use test. The drying symptoms, wrinkles and skin elasticity are shown in Table 2 in terms of the number of panels who answered that the skin after 3 months was moistened and the wrinkles and skin elasticity were improved compared to before use. Regarding the roughness of the skin, the skin condition was scored according to the criteria shown in Table 3, and the results before and after the end of the use test were compared in Table 4 based on the average value of 20 persons.
【0026】[0026]
【表2】 [Table 2]
【0027】[0027]
【表3】 [Table 3]
【0028】[0028]
【表4】 [Table 4]
【0029】表2に示したとおり、本発明の実施例使用
群では、9割以上のパネラーで乾燥症状,しわ,皮膚弾
性に改善が認められた。一方、比較例1〜比較例5使用
群においては、各種成分を配合していない比較例6より
は、乾燥症状,しわ,弾性の改善傾向が認められたが、
明確な改善傾向が認められたパネラーはすべて9名以下
であった。また、表4に示されるように、本発明の実施
例使用群では全パネラーにおいて肌荒れの改善傾向が認
められ、殆どのパネラーにおいて、皮溝,皮丘が明瞭に
認められるに至っていた。これに対し、各種成分を単独
で配合した比較例1〜比較例5においては、各種成分を
配合していない比較例6より皮膚の状態が改善されてい
たが、皮溝が平坦で皮丘の形が不明瞭な状態にとどまっ
ていた。As shown in Table 2, in the group using the examples of the present invention, 90% or more of panelists showed improvement in dryness, wrinkles and skin elasticity. On the other hand, in the use groups of Comparative Examples 1 to 5, the drying symptoms, wrinkles, and the tendency of improvement in elasticity were observed as compared with Comparative Example 6 in which various components were not blended.
No more than nine panelists showed a clear improvement trend. Further, as shown in Table 4, in the group using the example of the present invention, improvement tendency of the skin roughness was observed in all the panelists, and in most of the panelists, the skin sulcus and skin ridges were clearly observed. On the other hand, in Comparative Examples 1 to 5 in which various components were independently blended, the skin condition was improved compared to Comparative Example 6 in which various components were not blended. The shape remained ambiguous.
【0030】なお、本発明の実施例1〜実施例4につい
ては、上記使用試験期間中に含有成分の析出,分離,凝
集,変臭,変色といった製剤の状態変化は全く見られな
かった。また、各実施例使用群において、皮膚刺激性反
応や皮膚感作性反応を示したパネラーは存在しなかっ
た。In Examples 1 to 4 of the present invention, no change in the state of the preparation such as precipitation, separation, agglomeration, discoloration, and discoloration of the components was observed during the use test period. In addition, in each group used in Examples, there was no paneler showing a skin irritating reaction or a skin sensitizing reaction.
【0031】続いて本発明の他の実施例の処方を示す。Next, the formulation of another embodiment of the present invention will be described.
【0032】 [実施例5]養毛剤 (1)精製水 50.0(重量%) (2)エタノール 49.2 (3)タラ皮由来エラスチン溶液(製造例1) 0.3 (4)アラントイン 0.5 製法:(1)から(4)の成分を混合,均一化する。Example 5 Hair restorer (1) Purified water 50.0 (% by weight) (2) Ethanol 49.2 (3) Elastin solution derived from cod skin (Production Example 1) 0.3 (4) Allantoin 5 Production method: Mix and homogenize components (1) to (4).
【0033】 [実施例6] 美白液 (1)スクワラン 5.0(重量%) (2)白色ワセリン 2.0 (3)ミツロウ 0.5 (4)ソルビタンセスキオレエート 0.8 (5)ポリオキシエチレンオレイルエーテル(20EO) 1.2 (6)パラオキシ安息香酸メチル 0.1 (7)プロピレングリコール 5.0 (8)精製水 58.6 (9)カルボキシビニルポリマー(1重量%水溶液) 20.0 (10)水酸化カリウム 0.1 (11)タラ皮由来エラスチン溶液(製造例1) 0.5 (12)エタノール 5.0 (13)ロイヤルゼリー 1.0 (14)香料 0.2 製法:(1)〜(5)の油相成分を混合し、75℃に加熱し
て溶解,均一化する。一方、(6)〜(8)の水相成分を混
合,溶解して75℃に加熱し、前記の油相成分を添加し
て予備乳化する。(9)を添加した後ホモミキサーにて均
一に乳化し、(10)を加えてpHを調整する。冷却後40
℃にて(11)〜(14)を添加,混合する。Example 6 Whitening Liquid (1) Squalane 5.0 (% by weight) (2) White Vaseline 2.0 (3) Beeswax 0.5 (4) Sorbitan Sesquioleate 0.8 (5) Poly Oxyethylene oleyl ether (20EO) 1.2 (6) Methyl paraoxybenzoate 0.1 (7) Propylene glycol 5.0 (8) Purified water 58.6 (9) Carboxyvinyl polymer (1% by weight aqueous solution) 0 (10) Potassium hydroxide 0.1 (11) Elastin solution derived from cod skin (Production Example 1) 0.5 (12) Ethanol 5.0 (13) Royal jelly 1.0 (14) Fragrance 0.2 Production method: The oil phase components (1) to (5) are mixed and heated to 75 ° C. to dissolve and homogenize. On the other hand, the aqueous phase components (6) to (8) are mixed and dissolved, heated to 75 ° C., and the oil phase component is added and pre-emulsified. After adding (9), the mixture is emulsified uniformly with a homomixer, and (10) is added to adjust the pH. 40 after cooling
Add (11) to (14) at ℃ and mix.
【0034】 [実施例7]皮膚用ローション (1)エタノール 10.0(重量%) (2)ヒドロキシエチルセルロース 1.0 (3)タラ皮由来エラスチン溶液(製造例1) 0.5 (4)パラオキシ安息香酸メチル 0.1 (5)グリセリン 7.0 (6)グアイアズレンスルホン酸ナトリウム 0.5 (7)精製水 80.9 製法:(1)〜(7)を混合し、均一とする。Example 7 Skin Lotion (1) Ethanol 10.0 (% by weight) (2) Hydroxyethylcellulose 1.0 (3) Cod skin-derived elastin solution (Production Example 1) 0.5 (4) Paraoxyl Methyl benzoate 0.1 (5) Glycerin 7.0 (6) Sodium guaiazulene sulfonate 0.5 (7) Purified water 80.9 Production method: Mix (1) to (7) to make uniform.
【0035】 [実施例8]皮膚用乳剤 (1)ステアリン酸 0.2(重量%) (2)セタノール 1.5 (3)ワセリン 3.0 (4)流動パラフィン 7.0 (5)ポリオキシエチレン(10EO)モノオレイン酸エステル 1.5 (6)乳酸菌抽出物 0.5 (7)グリセリン 5.0 (8)パラオキシ安息香酸メチル 0.1 (9)トリエタノールアミン 1.0 (10)精製水 79.2 (11)タラ皮由来エラスチン溶液(製造例1) 1.0 製法:(1)〜(6)の油相成分を混合,加熱して均一に溶
解し、70℃に保つ。一方、(7)〜(10)の水相成分を混
合,加熱して均一とし、70℃とする。この水相成分に
油相成分を撹拌しながら徐々に添加して乳化し、冷却し
た後40℃にて(11)の成分を添加,混合する。Example 8 Skin Emulsion (1) Stearic acid 0.2 (% by weight) (2) Cetanol 1.5 (3) Vaseline 3.0 (4) Liquid paraffin 7.0 (5) Polyoxy Ethylene (10EO) monooleate 1.5 (6) Lactic acid bacteria extract 0.5 (7) Glycerin 5.0 (8) Methyl paraoxybenzoate 0.1 (9) Triethanolamine 1.0 (10) Purification Water 79.2 (11) Cod skin-derived elastin solution (Production Example 1) 1.0 Production method: The oil phase components (1) to (6) are mixed, heated and uniformly dissolved, and kept at 70 ° C. On the other hand, the aqueous phase components (7) to (10) are mixed and heated to be uniform, and the temperature is set to 70 ° C. The oil phase component is gradually added to the aqueous phase component while stirring to emulsify, and after cooling, the component (11) is added and mixed at 40 ° C.
【0036】 [実施例9]皮膚用ゲル剤 (1)精製水 89.3(重量%) (2)カルボキシビニルポリマー 0.5 (3)ジプロピレングリコール 8.0 (4)パラオキシ安息香酸メチル 0.1 (5)水酸化カリウム 0.1 (6)タラ皮由来エラスチン溶液(製造例1) 1.0 (7)胎盤抽出物 1.0 製法:(1)に(2)を均一に溶解した後、(3)に(4)を溶
解して添加し、次いで(5)を加えて増粘させ、(6),
(7)の成分を添加する。Example 9 Skin Gel (1) Purified Water 89.3 (% by weight) (2) Carboxyvinyl Polymer 0.5 (3) Dipropylene Glycol 8.0 (4) Methyl Paraoxybenzoate 0 0.1 (5) Potassium hydroxide 0.1 (6) Cod skin-derived elastin solution (Production Example 1) 1.0 (7) Placental extract 1.0 Production method: (2) was uniformly dissolved in (1) Then, (4) was dissolved and added to (3), and then (5) was added to increase the viscosity, (6),
Add the component of (7).
【0037】 [実施例10]皮膚用クリーム (1)ミツロウ 6.0(重量%) (2)セタノール 5.0 (3)還元ラノリン 8.0 (4)スクワラン 29.5 (5)親油型グリセリルモノステアリン酸エステル 4.0 (6)ポリオキシエチレン(20EO) ソルビタンモノラウリン酸エステル 5.0 (7)プロピレングリコール 5.0 (8)パラオキシ安息香酸メチル 0.1 (9)精製水 35.4 (10)タラ皮由来エラスチン溶液(製造例1) 1.0 (11)乳酸ナトリウム 1.0 製法:(1)〜(6)の油相成分を混合,溶解して75℃に
加熱する。一方、(7)〜(9)の水相成分を混合,溶解し
て75℃に加熱する。次いで、上記水相成分に油相成分
を添加して予備乳化した後、ホモミキサーにて均一に乳
化し、冷却後40℃にて(10),(11)の成分を添加,混合
する。Example 10 Skin Cream (1) Beeswax 6.0 (% by weight) (2) Cetanol 5.0 (3) Reduced Lanolin 8.0 (4) Squalane 29.5 (5) Lipophilic type Glyceryl monostearate 4.0 (6) Polyoxyethylene (20EO) sorbitan monolaurate 5.0 (7) Propylene glycol 5.0 (8) Methyl parahydroxybenzoate 0.1 (9) Purified water 35.4 (10) Elastin solution derived from cod skin (Production Example 1) 1.0 (11) Sodium lactate 1.0 Production method: The oil phase components (1) to (6) are mixed and dissolved and heated to 75 ° C. On the other hand, the aqueous phase components (7) to (9) are mixed and dissolved and heated to 75 ° C. Next, the oil phase component is added to the water phase component and preliminarily emulsified, and then uniformly emulsified by a homomixer. After cooling, the components (10) and (11) are added and mixed at 40 ° C.
【0038】 [実施例11]水中油型乳剤性軟膏 (1)白色ワセリン 25.0(重量%) (2)ステアリルアルコール 25.0 (3)グリセリン 10.0 (4)ラウリル硫酸ナトリウム 1.0 (5)パラオキシ安息香酸メチル 0.1 (6)精製水 36.9 (7)タラ皮由来エラスチン溶液(製造例1) 1.0 (8)乳酸菌発酵液 1.0 製法:(1)〜(4)の油相成分を混合,溶解して均一と
し、75℃に加熱する。一方、(5)を(6)に溶解して7
5℃に加熱し、これに前記油相成分を添加して乳化し、
冷却後40℃にて(7),(8)の成分を添加,混合す
る。[Example 11] Oil-in-water emulsion ointment (1) White petrolatum 25.0 (wt%) (2) Stearyl alcohol 25.0 (3) Glycerin 10.0 (4) Sodium lauryl sulfate 1.0 (5) Methyl paraoxybenzoate 0.1 (6) Purified water 36.9 (7) Cod skin-derived elastin solution (Production Example 1) 1.0 (8) Lactic acid bacterium fermented liquid 1.0 Production method: (1) to ( The oil phase component of 4) is mixed and dissolved to make it uniform, and heated to 75 ° C. On the other hand, dissolve (5) in (6)
Heat to 5 ° C, add the oil phase component to this and emulsify,
After cooling, the components (7) and (8) are added and mixed at 40 ° C.
【0039】 [実施例12]化粧水 (1)エタノール 10.0(重量%) (2)1,3-ブチレングリコール 10.0 (3)タラ皮由来エラスチン溶液(製造例1) 0.5 (4)グリチルリチン酸ジカリウム 0.5 (5)香料 0.1 (6)精製水 78.9 製法:(1)〜(5)を順次(6)に添加して均一に混合,溶
解する。Example 12 Lotion (1) Ethanol 10.0 (% by weight) (2) 1,3-butylene glycol 10.0 (3) Cod skin-derived elastin solution (Production Example 1) 0.5 ( 4) Dipotassium glycyrrhizinate 0.5 (5) Fragrance 0.1 (6) Purified water 78.9 Production method: (1) to (5) are sequentially added to (6) and uniformly mixed and dissolved.
【0040】 [実施例13]油中水乳化型エモリエントクリーム (1)流動パラフィン 36.0(重量%) (2)マイクロクリスタリンワックス 2.0 (3)ワセリン 5.0 (4)ジグリセリルオレイン酸エステル 5.0 (5)γ−オリザノール 1.0 (6)プロピレングリコール 3.0 (7)パラオキシ安息香酸メチル 0.1 (8)精製水 47.3 (9)タラ皮由来エラスチン溶液(製造例1) 0.5 (10)香料 0.1 製法:(1)〜(5)の油相成分を混合,溶解して均一と
し、75℃に加熱する。一方、(6)〜(9)の水相成分を
混合,溶解して均一とし、75℃に加熱し、前記油相成
分に添加し、ホモミキサーにて乳化する。冷却後40℃
にて(10)の成分を添加,混合する。Example 13 Water-in-oil emulsifying emollient cream (1) Liquid paraffin 36.0 (% by weight) (2) Microcrystalline wax 2.0 (3) Vaseline 5.0 (4) Diglyceryl oleic acid Ester 5.0 (5) γ-oryzanol 1.0 (6) Propylene glycol 3.0 (7) Methyl paraoxybenzoate 0.1 (8) Purified water 47.3 (9) Cod skin-derived elastin solution (Production example) 1) 0.5 (10) Fragrance 0.1 Production method: The oil phase components (1) to (5) are mixed and dissolved to make uniform, and heated to 75 ° C. On the other hand, the aqueous phase components (6) to (9) are mixed and dissolved to make uniform, heated to 75 ° C., added to the oil phase component, and emulsified by a homomixer. 40 ° C after cooling
Add and mix component (10) with.
【0041】 [実施例14]メイクアップベースクリーム (1)ステアリン酸 12.0(重量%) (2)セタノール 2.0 (3)グリセリルトリ-2-エチルヘキサン酸エステル 2.5 (4)自己乳化型グリセリルモノステアリン酸エステル 2.0 (5)プロピレングリコール 10.0 (6)水酸化カリウム 0.3 (7)精製水 67.6 (8)酸化チタン 1.0 (9)ベンガラ 0.1 (10)黄酸化鉄 0.4 (11)香料 0.1 (12)タラ皮由来エラスチン溶液(製造例1) 1.0 (13)鶏冠抽出物 1.0 製法:(1)〜(4)の油相成分を混合し、75℃に加熱し
て均一とする。一方、(5)〜(7)の成分を混合し、75
℃に加熱,溶解して均一とし、これに(8)〜(10)の顔料
を添加し、ホモミキサーにて均一に分散させ水相成分と
する。この水相成分に前記油相成分を添加し、ホモミキ
サーにて乳化した後冷却し、40℃にて(11)〜(13)の成
分を添加,混合する。Example 14 Makeup Base Cream (1) Stearic acid 12.0 (% by weight) (2) Cetanol 2.0 (3) Glyceryl tri-2-ethylhexanoate 2.5 (4) Self Emulsified glyceryl monostearate 2.0 (5) Propylene glycol 10.0 (6) Potassium hydroxide 0.3 (7) Purified water 67.6 (8) Titanium oxide 1.0 (9) Bengala 0.1 (10) Yellow iron oxide 0.4 (11) Fragrance 0.1 (12) Cod skin-derived elastin solution (Production Example 1) 1.0 (13) Cockscomb extract 1.0 Production method: (1) to (4) Are mixed and heated to 75 ° C. to make uniform. On the other hand, the components (5) to (7) were mixed and 75
The mixture was heated and melted at ℃ to make it uniform, and the pigments (8) to (10) were added thereto and uniformly dispersed with a homomixer to obtain an aqueous phase component. The oil phase component is added to the aqueous phase component, emulsified by a homomixer, cooled, and the components (11) to (13) are added and mixed at 40 ° C.
【0042】 [実施例15]乳液状ファンデーション (1)ステアリン酸 2.0(重量%) (2)スクワラン 5.0 (3)ミリスチン酸オクチルドデシル 5.0 (4)セタノール 1.0 (5)デカグリセリルモノイソパルミチン酸エステル 9.0 (6)1,3-ブチレングリコール 8.0 (7)水酸化カリウム 0.1 (8)パラオキシ安息香酸メチル 0.1 (9)精製水 50.8 (10)酸化チタン 9.0 (11)タルク 7.4 (12)ベンガラ 0.5 (13)黄酸化鉄 1.1 (14)黒酸化鉄 0.1 (15)香料 0.1 (16)タラ皮由来エラスチン溶液(製造例1) 0.5 (17)海水乾燥末(ニガリ) 0.3 製法:(1)〜(5)の油相成分を混合し、75℃に加熱し
て均一とする。一方、(6)〜(9)の水相成分を混合し、
75℃に加熱,溶解して均一とし、これに(10)〜(14)の
顔料を添加し、ホモミキサーにて均一に乳化した後冷却
し、40℃にて(15)〜(17)の成分を添加,混合する。Example 15 Emulsion Foundation (1) Stearic acid 2.0 (% by weight) (2) Squalane 5.0 (3) Octyldodecyl myristate 5.0 (4) Cetanol 1.0 (5) Decaglyceryl monoisopalmitate 9.0 (6) 1,3-butylene glycol 8.0 (7) Potassium hydroxide 0.1 (8) Methyl parahydroxybenzoate 0.1 (9) Purified water 50.8 ( 10) Titanium oxide 9.0 (11) Talc 7.4 (12) Bengala 0.5 (13) Yellow iron oxide 1.1 (14) Black iron oxide 0.1 (15) Fragrance 0.1 (16) Cod Skin-derived elastin solution (Production Example 1) 0.5 (17) Dried seawater powder (Nigari) 0.3 Production method: Mix oil phase components (1) to (5) and heat to 75 ° C to make uniform . On the other hand, the aqueous phase components (6) to (9) are mixed,
Heat and dissolve to 75 ° C to make uniform, add the pigments of (10) to (14) to the mixture, emulsify uniformly with a homomixer, cool, and cool at 40 ° C to (15) to (17). Add and mix the ingredients.
【0043】 [実施例16]ハンドクリーム (1)セタノール 4.0(重量%) (2)ワセリン 2.0 (3)流動パラフィン 10.0 (4)グリセリルモノステアリン酸エステル 1.5 (5)ポリオキシエチレン(60EO) グリセリルイソステアリン酸エステル 2.5 (6)酢酸トコフェロール 0.5 (7)グリセリン 20.0 (8)パラオキシ安息香酸メチル 0.1 (9)精製水 57.4 (10)タラ皮由来エラスチン溶液(製造例1) 1.0 (11)血清除蛋白抽出物 1.0 製法:(1)〜(6)の油相成分を混合,溶解して75℃に
加熱する。一方、(7)〜(9)の水相成分を混合,溶解し
て75℃に加熱する。ついで、水相成分に油相成分を添
加して予備乳化した後、ホモミキサーにて均一に乳化し
て冷却し、40℃にて(10)及び(11)の成分を添加,混合
する。Example 16 Hand cream (1) Cetanol 4.0 (% by weight) (2) Vaseline 2.0 (3) Liquid paraffin 10.0 (4) Glyceryl monostearate 1.5 (5) Polyoxyethylene (60EO) glyceryl isostearate 2.5 (6) Tocopherol acetate 0.5 (7) Glycerin 20.0 (8) Methyl paraoxybenzoate 0.1 (9) Purified water 57.4 (10) Cod Skin-derived elastin solution (Production Example 1) 1.0 (11) Serum deproteinized extract 1.0 Production method: Mix and dissolve the oil phase components (1) to (6) and heat to 75 ° C. On the other hand, the aqueous phase components (7) to (9) are mixed and dissolved and heated to 75 ° C. Next, the oil phase component is added to the water phase component and pre-emulsified, then uniformly emulsified and cooled with a homomixer, and the components (10) and (11) are added and mixed at 40 ° C.
【0044】[0044]
【発明の効果】魚皮由来の加水分解エラスチン溶液と細
胞賦活成分,抗炎症成分を配合した皮膚外用剤は、保湿
作用及び真皮線維芽細胞活性化作用が相乗的に増強さ
れ、しわの発生、皮膚弾性の低下といった皮膚老化症状
の防止あるいは改善に有効であることが示された。According to the present invention, a skin external preparation containing a hydrolyzed elastin solution derived from fish skin and a cell activating component and an anti-inflammatory component has a moisturizing effect and a dermal fibroblast activating effect that are synergistically enhanced. It was shown to be effective in preventing or improving skin aging symptoms such as a decrease in skin elasticity.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) A61K 7/06 A61K 7/06 31/00 31/00 35/12 35/12 35/28 35/28 35/50 35/50 35/64 35/64 35/72 35/72 35/74 35/74 35/84 35/84 A 38/00 35/60 // A61K 35/60 37/02 Fターム(参考) 4C083 AA031 AA032 AA071 AA072 AA081 AA082 AA111 AA161 AA162 AB052 AB232 AB242 AB332 AB442 AC012 AC022 AC031 AC072 AC102 AC112 AC122 AC182 AC242 AC301 AC302 AC311 AC352 AC392 AC422 AC442 AC482 AC542 AC581 AC681 AC782 AD092 AD282 AD411 AD412 AD471 AD512 AD531 AD532 AD601 AD621 AD631 AD651 AD662 AD671 BB51 CC02 CC04 CC05 CC14 CC37 DD22 DD31 DD32 DD33 DD41 EE12 EE22 4C084 AA02 AA24 BA43 CA03 CA13 CA25 CA29 CA36 CA41 CA45 MA63 NA02 NA11 ZA891 ZA892 ZB221 ZB222 4C087 AA01 BB21 BB29 BB35 BB44 BB58 BC11 BC56 CA11 MA63 NA02 NA11 ZA89 ZB22 4C088 AA06 AC16 BA05 BA37 MA63 NA02 NA11 ZA89 ZB22 4C206 AA01 AA02 DA14 DA19 FA44 MA01 MA02 MA04 MA83 NA02 NA11 ZA89 ZB22 ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification symbol FI Theme coat ゛ (Reference) A61K 7/06 A61K 7/06 31/00 31/00 35/12 35/12 35/28 35/28 35 / 50 35/50 35/64 35/64 35/72 35/72 35/74 35/74 35/84 35/84 A 38/00 35/60 // A61K 35/60 37/02 F-term (reference) 4C083 AA031 AA032 AA071 AA072 AA081 AA082 AA111 AA161 AA162 AB052 AB232 AB242 AB332 AB442 AC012 AC022 AC031 AC072 AC102 AC112 AC122 AC182 AC242 AC301 AC302 AC311 AC352 AC392 AC422 AC442 AC482 AC542 AC581 AD681 AD681 AD681 AD681 AD681 AD6811 AD681 BB51 CC02 CC04 CC05 CC14 CC37 DD22 DD31 DD32 DD33 DD41 EE12 EE22 4C084 AA02 AA24 BA43 CA03 CA13 CA25 CA29 CA36 CA41 CA45 MA63 NA02 NA11 ZA891 ZA892 ZB221 ZB222 4C087 AA01 BB21 BB29 BB35 ZA44A88B88A11 6 AC16 BA05 BA37 MA63 NA02 NA11 ZA89 ZB22 4C206 AA01 AA02 DA14 DA19 FA44 MA01 MA02 MA04 MA83 NA02 NA11 ZA89 ZB22
Claims (3)
細胞賦活成分,抗炎症成分から選択される1種又は2種
以上の成分を含有する皮膚外用剤。1. A hydrolyzed elastin solution derived from fish skin,
An external preparation for skin containing one or more components selected from cell activating components and anti-inflammatory components.
ドロキシカルボン酸及びその塩並びに誘導体、ビタミン
C,ビタミンE,ビタミンP関連化合物を除くビタミン
様作用物質、核酸関連物質、血清除蛋白抽出物、脾臓抽
出物、胎盤抽出物、鶏冠抽出物、ロイヤルゼリー、霊芝
抽出物、酵母抽出物、乳酸菌抽出物、ビフィズス菌抽出
物、ニガリ成分から選択される1種又は2種以上であ
る、請求項1に記載の皮膚外用剤。2. The cell activating component is a 2-hydroxycarboxylic acid having 2 to 22 carbon atoms and salts and derivatives thereof, vitamin-like active substances excluding vitamin C, vitamin E and vitamin P-related compounds, nucleic acid-related substances, serum deprivation. One or more selected from protein extract, spleen extract, placenta extract, cockscomb extract, royal jelly, ganoderma extract, yeast extract, lactic acid bacteria extract, bifidobacterium extract, bittern component The external preparation for skin according to claim 1, which is present.
チルレチン酸,イソプロピルアミノカプロン酸,アズレ
ン,リゾチーム,サリチル酸,γ−オリザノール,アラ
ントイン及びそれらの誘導体並びにそれらの塩から選択
される1種又は2種以上である、請求項1に記載の皮膚
外用剤。3. The anti-inflammatory component is one or more selected from glycyrrhizic acid, glycyrrhetinic acid, isopropylaminocaproic acid, azulene, lysozyme, salicylic acid, γ-oryzanol, allantoin and derivatives thereof, and salts thereof. The external preparation for skin according to claim 1, which is present.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP25443199A JP2001072572A (en) | 1999-09-08 | 1999-09-08 | Skin preparation for external use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP25443199A JP2001072572A (en) | 1999-09-08 | 1999-09-08 | Skin preparation for external use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2001072572A true JP2001072572A (en) | 2001-03-21 |
Family
ID=17264902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP25443199A Pending JP2001072572A (en) | 1999-09-08 | 1999-09-08 | Skin preparation for external use |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2001072572A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2479035A (en) * | 2010-03-09 | 2011-09-28 | Lvmh Rech | Cosmetic composition comprising honey or royal jelly and a peptide |
| WO2015137419A1 (en) * | 2014-03-11 | 2015-09-17 | 北海道公立大学法人札幌医科大学 | Activator for mesenchymal stem cells, activated mesenchymal stem cells, and method for producing same |
| JP2024009897A (en) * | 2018-08-23 | 2024-01-23 | エルジー ハウスホールド アンド ヘルスケア リミテッド | Composition for promoting differentiation or proliferation of human adipose stem cells |
| US12090251B2 (en) | 2018-04-25 | 2024-09-17 | Sapporo Medical University | Cell sheet for transplantation into living body and method for producing same |
-
1999
- 1999-09-08 JP JP25443199A patent/JP2001072572A/en active Pending
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2479035A (en) * | 2010-03-09 | 2011-09-28 | Lvmh Rech | Cosmetic composition comprising honey or royal jelly and a peptide |
| JP2011201872A (en) * | 2010-03-09 | 2011-10-13 | Lvmh Recherche | Cosmetic or dermatological composition containing combination of honey and peptide |
| GB2479035B (en) * | 2010-03-09 | 2012-07-11 | Lvmh Rech | Cosmetic or dermatological composition comprising the combination of honey and a peptide |
| WO2015137419A1 (en) * | 2014-03-11 | 2015-09-17 | 北海道公立大学法人札幌医科大学 | Activator for mesenchymal stem cells, activated mesenchymal stem cells, and method for producing same |
| JPWO2015137419A1 (en) * | 2014-03-11 | 2017-04-06 | 北海道公立大学法人 札幌医科大学 | Activator of mesenchymal stem cells, activated mesenchymal stem cells and method for producing the same |
| US10512660B2 (en) | 2014-03-11 | 2019-12-24 | Sapporo Medical University | Activator for mesenchymal stem cells, activated mesenchymal stem cells, and method for producing same |
| US12090251B2 (en) | 2018-04-25 | 2024-09-17 | Sapporo Medical University | Cell sheet for transplantation into living body and method for producing same |
| JP2024009897A (en) * | 2018-08-23 | 2024-01-23 | エルジー ハウスホールド アンド ヘルスケア リミテッド | Composition for promoting differentiation or proliferation of human adipose stem cells |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101353628B1 (en) | Compounding ingredients for basic cosmetics and basic cosmetics | |
| JP2001002551A (en) | Agent for increasing hyaluronic acid content of horny layer | |
| JP2001206835A (en) | Collagen synthesis promoter and collagen metabolism activator | |
| JP3758794B2 (en) | Collagen production promoter and anti-aging skin external preparation containing the same | |
| JP2003048846A (en) | Collagenase inhibitor and anti-aging cosmetic | |
| JPH11158055A (en) | Skin lotion | |
| JP2000256398A (en) | Fish skin-derived collagen and cosmetics containing it | |
| JPH11193207A (en) | Preparation for external use for skin | |
| JP2003055190A (en) | Collagenase inhibitor and anti-aging cosmetic | |
| JP2002212087A (en) | External preparation for skin | |
| US20080153741A1 (en) | Compounding ingredients for cosmetic formulation for improving skinditch density and cosmetic | |
| JP2001081008A (en) | Skin preparation for external use keeping and improving the skin from chapping | |
| JP3881411B2 (en) | Composition suitable for external use | |
| JP5165299B2 (en) | Topical skin preparation | |
| JP2003034631A (en) | Fibroblast proliferation promoter and anti-aging cosmetic | |
| JPH05262635A (en) | Dermatic external preparation | |
| JPH069422A (en) | Promoter for biosynthesis of hyaluronic acid | |
| JP3278138B2 (en) | External preparation for skin | |
| JP4828077B2 (en) | Topical skin preparation | |
| JP2001072572A (en) | Skin preparation for external use | |
| JP3507635B2 (en) | Composition suitable for external use | |
| JP2001212445A (en) | Emulsifying agent | |
| JPH05301812A (en) | Skin external preparation | |
| JP2004026766A (en) | Skin care preparation for external use | |
| JP2001253817A (en) | Collagen synthesis promoter and method for producing the same and skin care preparation containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040901 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20050809 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050824 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20051227 |